Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(6/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(6/week)
News
United States
(507/week)
Manufacturing
(335/week)
Energy
(278/week)
Technology
(347/week)
Other Energy
(240/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Aprea Therapeutics AB
Aug 05, 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Apr 16, 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Apr 03, 2019
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
Mar 25, 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Feb 27, 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Dec 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
Nov 30, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
Jun 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
Apr 16, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago
Jan 04, 2018
Aprea Therapeutics Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco
Aug 02, 2017
Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer
Latest News
Apr 19, 2024
Construction Equipment Global Strategic Business Report 2024: Market to Reach $248.5 Billion by 2030 - Focus...
Apr 19, 2024
New Jersey Natural Gas to Reduce Fleet Emissions with Neste MY Renewable Diesel
Apr 19, 2024
VulnCheck Closes $7.95 Million in Seed Funding to Accelerate Momentum Amid Growing Demand for its Next-...
Apr 19, 2024
AEVEX Aerospace to Debut Atlas Loitering Munition at 2024 Army Aviation Mission Solutions Summit
Apr 19, 2024
Solar Sector Sees $8.1 Billion in Corporate Funding in Q1 2024, Reports Mercom Capital Group
Apr 19, 2024
US Consumers’ 2024 Sustainability Score Declines and Lags the Global Average, According to New Report
Apr 19, 2024
Kontoor Brands Declares Quarterly Dividend
Apr 19, 2024
American Water Honored as a 2024 VETS Indexes 5 Star Employer
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events